Top Page
Akeso, Inc.
(9926)
Akeso, Inc. (9926) vs. iShares MSCI Hong Kong ETF (EWH)
Akeso, Inc. Business Overview & Revenue Model
Akeso, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.51B | 2.12B | 4.53B | 837.66M | 225.63M | 0.00 |
| Gross Profit | 2.02B | 1.83B | 4.39B | 734.54M | 195.41M | -1.90M |
| EBITDA | -704.02M | -604.99M | 2.17B | -1.27B | -1.32B | -1.01B |
| Net Income | -846.01M | -514.51M | 2.03B | -1.17B | -1.07B | -1.04B |
Balance Sheet | ||||||
| Total Assets | 13.29B | 12.75B | 9.18B | 5.50B | 4.81B | 3.86B |
| Cash, Cash Equivalents and Short-Term Investments | 7.14B | 7.32B | 4.88B | 2.29B | 2.65B | 2.80B |
| Total Debt | 4.54B | 3.95B | 2.99B | 1.88B | 859.42M | 198.99M |
| Total Liabilities | 6.93B | 6.00B | 4.66B | 2.95B | 1.53B | 405.73M |
| Stockholders Equity | 6.44B | 6.81B | 4.69B | 2.64B | 3.16B | 3.19B |
Cash Flow | ||||||
| Free Cash Flow | -163.83M | -1.11B | 1.59B | -2.02B | -1.71B | -1.06B |
| Operating Cash Flow | -408.62M | -527.62M | 2.47B | -1.24B | -1.00B | -617.77M |
| Investing Cash Flow | -3.48B | -1.52B | -4.00B | -889.75M | -579.59M | -555.70M |
| Financing Cash Flow | 2.84B | 3.39B | 960.89M | 1.49B | 1.59B | 2.88B |
Akeso, Inc. Technical Analysis
Akeso, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | HK$150.36B | 10.60 | 9.79% | ― | 16.90% | 63.11% | |
61 Neutral | $144.54B | 36.49 | 8.22% | ― | 52.78% | ― | |
54 Neutral | HK$109.63B | 12.76 | 11.72% | 1.40% | 13.69% | 50.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$60.10B | 51.47 | -39.64% | ― | 46.14% | 39.56% | |
45 Neutral | HK$98.84B | -32.76 | -14.40% | ― | 33.46% | -7.60% | |
38 Underperform | HK$32.12B | -22.62 | -15.06% | ― | 38.56% | 48.26% |
Akeso, Inc. Corporate Events
Akeso, Inc. has granted Hubei JumpCan Pharmaceutical’s subsidiaries exclusive rights to commercialize its newly approved PCSK9 monoclonal antibody ebronucimab injection (伊喜寧®) in mainland China, in exchange for an RMB80 million licence fee and up to RMB10 million in milestone payments. Under the deal, JumpCan will take over commercialization and sales of the drug, which has been approved for primary hypercholesterolemia and mixed hyperlipidemia, included in China’s National Reimbursement Drug List, and recommended in key national clinical guidelines, positioning Akeso to monetize its innovation while leveraging JumpCan’s extensive domestic sales network and potentially accelerating market penetration in the fast-growing cardiovascular therapeutics segment.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$116.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso, Inc. has provided additional details on its long-term contract manufacturing arrangement involving CTTQ-Akeso, Akeso Biopharma, Chai Tai Tianqing and Nanjing Tianqing, clarifying that the supplemental agreement for MAb product manufacturing runs until August 29, 2039, with the option for the parties to negotiate a new agreement upon expiry, subject to compliance with Hong Kong listing requirements. The company elaborated that procurement pricing for MAb products will be based on Nanjing Tianqing’s actual manufacturing costs plus a reasonable profit margin benchmarked against listed contract manufacturers, and that proposed annual procurement caps factor in expected demand growth driven by the inclusion of penpulimab in China’s National Reimbursement Drug List from January 2026, anticipated new indications, potential new markets, and a single-digit buffer for unforeseen increases, while also disclosing more detail on the shareholder structure of Chia Tai Tianqing.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$116.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso has updated the contractual framework governing the manufacturing of its monoclonal antibody products for its joint venture CTTQ-Akeso, which was established with partner Chia Tai Tianqing. Under a supplemental agreement effective 1 January 2025, CTTQ-Akeso will, in principle, source equal quantities of MAb products from both Akeso Biopharma and Nanjing Tianqing, reflecting a shared production arrangement between the two manufacturing partners. Because CTTQ-Akeso is no longer classified as an insignificant subsidiary, Chia Tai Tianqing and its 95%-owned Nanjing Tianqing have become connected persons at the subsidiary level, making the supplemental agreement a continuing connected transaction subject to Hong Kong listing rule disclosure and annual review requirements. Akeso acknowledged that this supplemental agreement should have been announced earlier and attributed the delay to an inadvertent oversight, and it has appointed Rainbow Capital as independent financial adviser to justify the longer-than-three-year term of the agreement, underscoring the company’s need to align its collaboration structures with ongoing regulatory compliance obligations.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$130.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
Akeso, Inc. announced that all approved indications of its five marketed innovative drugs have been included in China’s 2025 National Reimbursement Drug List (NRDL), effective January 1, 2026. This inclusion is expected to enhance the company’s market presence and accessibility of its treatments, potentially benefiting patients with various conditions such as cancer, hypercholesterolemia, and psoriasis.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$130.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.